XENON PHARMACEUTICALS INC (XENE)
CA98420N1050 - Common Stock
XENE gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. XENE has a great financial health rating, but its profitability evaluates not so good. XENE is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year XENE has reported negative net income.
XENE had a negative operating cash flow in the past year.
In the past 5 years XENE always reported negative net income.
In the past 5 years XENE always reported negative operating cash flow.
1.2 Ratios
XENE has a better Return On Assets (-18.90%) than 78.76% of its industry peers.
XENE has a Return On Equity of -19.66%. This is amongst the best in the industry. XENE outperforms 85.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.9% | ||
| ROE | -19.66% | ||
| ROIC | N/A |
ROA(3y)-16.32%
ROA(5y)-18.17%
ROE(3y)-17%
ROE(5y)-22.17%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for XENE so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
XENE does not have a ROIC to compare to the WACC, probably because it is not profitable.
XENE has more shares outstanding than it did 1 year ago.
The number of shares outstanding for XENE has been increased compared to 5 years ago.
XENE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
XENE has an Altman-Z score of 47.32. This indicates that XENE is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 47.32, XENE belongs to the top of the industry, outperforming 98.23% of the companies in the same industry.
XENE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 47.32 |
ROIC/WACCN/A
WACC10.53%
2.3 Liquidity
A Current Ratio of 23.65 indicates that XENE has no problem at all paying its short term obligations.
XENE has a Current ratio of 23.65. This is amongst the best in the industry. XENE outperforms 96.46% of its industry peers.
XENE has a Quick Ratio of 23.65. This indicates that XENE is financially healthy and has no problem in meeting its short term obligations.
XENE has a Quick ratio of 23.65. This is amongst the best in the industry. XENE outperforms 96.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 23.65 | ||
| Quick Ratio | 23.65 |
3. Growth
3.1 Past
The earnings per share for XENE have decreased by -6.42% in the last year.
The Revenue for XENE has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-6.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.96%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, XENE will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.89% on average per year.
Based on estimates for the next years, XENE will show a very strong growth in Revenue. The Revenue will grow by 199.43% on average per year.
EPS Next Y-15.82%
EPS Next 2Y-16.16%
EPS Next 3Y-13.39%
EPS Next 5Y13.89%
Revenue Next Year-85.78%
Revenue Next 2Y55.47%
Revenue Next 3Y175.77%
Revenue Next 5Y199.43%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
XENE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year XENE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as XENE's earnings are expected to decrease with -13.39% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-16.16%
EPS Next 3Y-13.39%
5. Dividend
5.1 Amount
No dividends for XENE!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
XENON PHARMACEUTICALS INC
NASDAQ:XENE (12/20/2024, 8:00:02 PM)
After market: 38.63 0 (0%)38.63
-0.27 (-0.69%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners99.47%
Inst Owner Change2.21%
Ins Owners0.79%
Ins Owner Change0%
Market Cap2.95B
Analysts87.5
Price Target57.85 (49.75%)
Short Float %3.86%
Short Ratio7.48
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.45%
Min EPS beat(2)7.55%
Max EPS beat(2)17.35%
EPS beat(4)3
Avg EPS beat(4)6.08%
Min EPS beat(4)-1.23%
Max EPS beat(4)17.35%
EPS beat(8)5
Avg EPS beat(8)3.04%
EPS beat(12)7
Avg EPS beat(12)0.47%
EPS beat(16)10
Avg EPS beat(16)5.84%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-100%
Min Revenue beat(4)-100%
Max Revenue beat(4)-100%
Revenue beat(8)0
Avg Revenue beat(8)-85.26%
Revenue beat(12)1
Avg Revenue beat(12)-57.75%
Revenue beat(16)4
Avg Revenue beat(16)-32.98%
PT rev (1m)-0.21%
PT rev (3m)-1.63%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-0.22%
EPS NY rev (3m)1.05%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-5.88%
Revenue NY rev (3m)-11.76%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.17 | ||
| P/tB | 3.17 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.82
EYN/A
EPS(NY)-3.67
Fwd EYN/A
FCF(TTM)-1.98
FCFYN/A
OCF(TTM)-1.91
OCFYN/A
SpS0
BVpS12.17
TBVpS12.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.9% | ||
| ROE | -19.66% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-16.32%
ROA(5y)-18.17%
ROE(3y)-17%
ROE(5y)-22.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 158.63% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 23.65 | ||
| Quick Ratio | 23.65 | ||
| Altman-Z | 47.32 |
F-Score2
WACC10.53%
ROIC/WACCN/A
Cap/Depr(3y)187.43%
Cap/Depr(5y)252.63%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.96%
EPS Next Y-15.82%
EPS Next 2Y-16.16%
EPS Next 3Y-13.39%
EPS Next 5Y13.89%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-85.78%
Revenue Next 2Y55.47%
Revenue Next 3Y175.77%
Revenue Next 5Y199.43%
EBIT growth 1Y-65.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-28.02%
EBIT Next 3Y-12.02%
EBIT Next 5YN/A
FCF growth 1Y-48.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-47.64%
OCF growth 3YN/A
OCF growth 5YN/A